Clinical Trial Search

Primary: Percentage of Assessable Vascular Segments Using Gadobutrol-Enhanced MRA and Unenhanced MRA — 95.0; 72.7; 88.2; 24.4 percentage of segments — p=<0.0001

Primary: Change From Baseline in Weight at Week 52 — 0.25 kg

Primary: Percentage of Assessable Vascular Segments Using Gadobutrol-Enhanced MRA and Unenhanced MRA — 95.9; 77.6; 98.1; 81.7 Percentage of segments — p=<0.000

Primary: Technical Failure Rate — 4.65; 29.44; 1.77; 16.70 percentage of arterial segments

Primary: Overall Survival — 390; 405 Days

Primary: Change From Baseline to End of Treatment in the Mean Seated Trough Cuff Diastolic Blood Pressure (DBP). — -15.7; -13.2; -9.5 mmHg — p=0.025

Primary: Technical Failure Rate — 3.55; 29.22; 1.57; 17.65 percentage of arterial segments

Primary: Score on the Observational Scale of Behavioral Distress Revised (OSBD-R) — 5.48; 18.92 units on a scale

Primary: Modified Rankin Scale — 2; 2 units on a scale — p=0.28

Primary: Number of Subjects With Serious Adverse Events (SAEs) — 1; 1; 0 Subjects

Primary: Difference in RAVLT Total T-Score Between Treatments — 57.76; 56.11; 53.08; 42.76 T-score — p=<0.01

Primary: Participants With Adverse Experiences During Weeks 0-12 (Double-Blind Period) — 105; 84; 6; 3 participants

Primary: Number of Randomized Patients Achieving Early Virologic Response (EVR) - Negative PCR Result for HCV RNA (< 15 IU/ml) or ≥ 2log10 Decrease of Viral Load After 12 Weeks…

Primary: Change in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Systolic Blood Pressure (maSBP) — -13.93; -0.82 mmHg

Primary: Percentage of Participants Aged 4 Years or Younger With at Least One Complete Response at Week 56 — 94.1 Percentage of participants